|  |
| --- |
|  |
| Book Name: | [**Medical Science: Recent Advances and Applications**](https://bookstore.bookpi.org/product/medical-science-recent-advances-and-applications-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_6179** |
| Title of the Manuscript:  | **NRAS, KRAS, BRAF and PIK3CA mutation rates and the association with clinicopathological features in Ugandan colorectal cancer patients** |
| Type of the Article | **Book Chapter** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment**Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | Important. Fills a significant gap in the understanding of the genetic landscape of colorectal cancer in Uganda. There, where such data seems to be scarce. By profiling KRAS, NRAS, BRAF, and PIK3CA mutations, the study provides a foundation for future work on targeted therapies and prognostic markers in an underrepresented population. Meaningful comparisons with data from Western and Asian cohorts noted.It highlights both similarities and differences that may have clinical implications. Overall, valuable knowledge on 🡪 molecular drivers of colorectal cancer. |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | Yes. But may consider: Mutational Spectrum of NRAS, KRAS, BRAF, and PIK3CA and Their Clinicopathological Associations in Ugandan Colorectal Cancer Patients. |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | Abstract broadly clear.  The methodology section could be streamlined a bit. Terms like “pyrosequencing and PCR” are okay ---, but too much details on inclusion/exclusion or sample type could be omitted.Rather (briefly) highlight that this is the first study from Uganda analyzing all four genes simultaneously. Try underlining the implications of the findings in the conclusion. Something like say 🡪 how these results could influence targeted therapy or cancer management strategies in Sub-Saharan Africa. |  |
| **Is the manuscript scientifically, correct? Please write here.**  | Yes. The study design, use of NGS for mutational profiling, and the statistical methods applied are appropriate.Did not notice any major methodological flaws.But relatively small sample size and retrospective nature of part of the cohort should be kept in mind when interpreting the results. Interestingly, these limitations are already acknowledged by the authors.Appreciated. Adds credibility. |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | The references broadly sufficient.Mix of global and regional studies.Mostly (several) 🡪 past 10–12 years. Foud couple of landmark papers on KRAS, NRAS, BRAF, and PIK3CA mutations mentioned.Also found 🡪comparative studies from other countries. Suggestion: Try adding 🡪 more recent large-scale genomic studies of colorectal cancer ( I would say 🡪 from The Cancer Genome Atlas or other African cohorts. Try writing a discussion para on clinical implications – and there mention a couple of the latest reviews or guidelines on targeted therapy in CRC (such as say … … ESMO or NCCN guideline updates from the last may be 🡪 2–3 years). |  |
| Is the language/English quality of the article suitable for scholarly communications? | Broadly okay. A few grammatical errors. “tuumours” -🡪 “tumours,” or shifts between American and British spelling here and there. Overall – okay.  |  |
| Optional/General comments |  |  |

|  |
| --- |
| **PART 2:**  |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  |  |  |

**Reviewer details:**

**Pratap N Mukhopadhyaya, India**